Piramal Pharma Bolsters Biologics Portfolio with Majority Stake in Yapan Bio
Hyderabad, India – [Date of Publication] – Piramal Pharma Ltd. (PPL) has significantly expanded its footprint in the burgeoning biologics sector by acquiring an additional 40.67% stake in Yapan Bio Private Limited, a Hyderabad-based Contract Development and Manufacturing Organization (CDMO) specializing in vaccines and biologics. This strategic move, valued at $7.95 million, elevates PPL’s ownership in Yapan Bio to a controlling 74%, effectively making the company a subsidiary.
This acquisition is a pivotal step in PPL’s overarching strategy to solidify its presence in the biologics market, a critical and rapidly evolving segment of the pharmaceutical industry. By fully integrating Yapan Bio’s advanced large molecule capabilities into its existing service offerings, PPL aims to provide customers with a more comprehensive suite of solutions. This will enable the company to enhance its capacity for developing and scaling complex biologic therapies with increased efficiency and speed. Yapan Bio will continue its operations under the umbrella of Piramal Pharma Solutions (PPS), PPL’s dedicated CDMO arm.
The integration of Yapan Bio’s expertise is also expected to further strengthen PPS’s innovative ADCelerate platform. This fixed-price, integrated solution is designed to streamline Phase I Antibody-Drug Conjugate (ADC) development, from research and development to Good Manufacturing Practice (GMP) standards, in an impressive timeframe of just 12 months. This reinforcement underscores PPL’s commitment to delivering life-saving ADCs to market with unparalleled speed and consistency, addressing a critical need in oncology and other therapeutic areas.
Peter DeYoung, CEO of Piramal Global Pharma, articulated the strategic importance of this investment, stating, "This strategic investment doesn’t just fuel our long-term growth; it also puts Patient Centricity into action. By integrating Yapan Bio’s specialized expertise into our global network, we’re empowering our partners to meet a rising global demand for complex biologics and helping patients worldwide secure continued access to the therapies they need." DeYoung has been lauded for his instrumental role in transforming Piramal Pharma into a more focused and globally integrated pharmaceutical entity.
This latest move by Piramal Pharma highlights a growing trend within the pharmaceutical industry towards strategic mergers and acquisitions, particularly in specialized and high-growth areas like biologics and CDMO services. As the demand for complex biologic therapies continues to rise, companies are actively seeking to expand their capabilities and market reach through such strategic investments.
For a broader overview of the pharmaceutical industry’s dynamic landscape of mergers and acquisitions, readers can explore Contract Pharma’s comprehensive Pharmaceutical Industry Mergers & Acquisitions Roundup for 2024.
